Huang Yan, Zhou Yuzhen, Chen Huixian, Xu Yanyi
Department of Obstetrics and Gynecology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, Jiangsu, 215101, China.
Open Med (Wars). 2024 Mar 5;19(1):20230794. doi: 10.1515/med-2023-0794. eCollection 2024.
This study aimed to investigate the changes of serum carbohydrate antigen 125 (CA125) and prostaglandin E2 (PGE2) in patients with adenomyosis before and after treatment with high-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone agonist (GnRH-a). One hundred and sixty-five patients with adenomyosis who received HIFU combined with GnRH-a were selected as case group. Sixty-five healthy women who underwent physical examination at the same time were taken as normal control group. At the end of follow-up 6 months after treatment, the case group were divided into effective subgroup and ineffective subgroup according to clinical efficacy. Changes of serum CA125 and PGE2 were analyzed. Serum CA125 and PGE2 levels in the case group were higher than those in the normal control group before treatment (both < 0.001). Serum CA125 and PGE2 levels in the case group 6 months after treatment were lower than those before treatment (both < 0.001). There was no difference in serum CA125 and PGE2 levels between effective subgroup and ineffective subgroup before treatment ( = 0.351, 0.284, respectively). Serum CA125 and PGE2 levels in the effective subgroup were lower than those in the ineffective subgroup 6 months after treatment (both < 0.001). Serum CA125 and PGE2 may be involved in the development of adenomyosis, and their expression levels may be related to the prognosis of patients. Levels of serum CA125 and PGE2 in patients with adenomyosis decrease after treatment with HIFU combined with GnRH-a. The detection of serum CA125 and PGE2 may be used as an index to diagnose adenomyosis and evaluate the therapeutic effect of HIFU combined with GnRH-a.
本研究旨在探讨高强度聚焦超声（HIFU）联合促性腺激素释放激素激动剂（GnRH-a）治疗前后子宫腺肌病患者血清糖类抗原125（CA125）和前列腺素E2（PGE2）的变化。选取165例接受HIFU联合GnRH-a治疗的子宫腺肌病患者作为病例组。选取同期进行体检的65例健康女性作为正常对照组。治疗后6个月随访结束时，根据临床疗效将病例组分为有效亚组和无效亚组。分析血清CA125和PGE2的变化。治疗前病例组血清CA125和PGE2水平均高于正常对照组（均P<0.001）。治疗后6个月病例组血清CA125和PGE2水平均低于治疗前（均P<0.001）。治疗前有效亚组和无效亚组血清CA125和PGE2水平无差异（分别为P = 0.351、0.284）。治疗后6个月有效亚组血清CA125和PGE2水平低于无效亚组（均P<0.001）。血清CA125和PGE2可能参与子宫腺肌病的发生发展，其表达水平可能与患者预后有关。HIFU联合GnRH-a治疗后子宫腺肌病患者血清CA125和PGE2水平降低。血清CA125和PGE2的检测可作为诊断子宫腺肌病及评估HIFU联合GnRH-a治疗效果的指标。
